Evidence map›Paper›PMID 32574204›Full record

ArticlePLoS pathogens2020

Various miRNAs compensate the role of miR-122 on HCV replication.

Chikako Ono, Takasuke Fukuhara, Songling Li, Jian Wang, Asuka Sato, Takuma Izumi, Yuzy Fauzyah, Takuya Yamamoto, Yuhei Morioka, Nikolay V Dokholyan and 2 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Chikako OnoDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Takasuke FukuharaDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.ORCID 0000-0001-5471-8331
Songling LiDepartment of Genome Informatics, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Jian WangDepartment of Pharmacology, Penn State University College of Medicine, Hershey, Pennsylvania, United States of America.ORCID 0000-0001-7768-2802
Asuka SatoDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Takuma IzumiDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Yuzy FauzyahDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Takuya YamamotoDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Yuhei MoriokaDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Nikolay V DokholyanDepartment of Pharmacology, Penn State University College of Medicine, Hershey, Pennsylvania, United States of America.ORCID 0000-0002-8225-4025
Daron M StandleyDepartment of Genome Informatics, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Yoshiharu MatsuuraDepartment of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.ORCID 0000-0001-9091-8285
The University of Osaka · JPPennsylvania State University · US

Funding

Nanoscale programming of cellular and physiological phenotypes: EquipmentR35GM134864 · NIGMS · UNIVERSITY OF VIRGINIA · PI Nikolay Dokholyan · 2020 to 2026
$5.2M
Integrating cheminformatics and molecular simulations for virtual drug screeningR01GM114015 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DOKHOLYAN, NIKOLAY · 2016 to 2019
$1.1M
NIGMS NIH HHS R01 GM114015NIGMS NIH HHS R35 GM134864
6 · The paper itself

Abstract

One of the determinants for tissue tropism of hepatitis C virus (HCV) is miR-122, a liver-specific microRNA. Recently, it has been reported that interaction of miR-122 to HCV RNA induces a conformational change of the 5'UTR internal ribosome entry site (IRES) structure to form stem-loop II structure (SLII) and hijack of translating 80S ribosome through the binding of SLIII to 40S subunit, which leads to efficient translation. On the other hand, low levels of HCV-RNA replication have also been detected in some non-hepatic cells; however, the details of extrahepatic replication remain unknown. These observations suggest the possibility that miRNAs other than miR-122 can support efficient replication of HCV-RNA in non-hepatic cells. Here, we identified a number of such miRNAs and show that they could be divided into two groups: those that bind HCV-RNA at two locations (miR-122 binding sites I and II), in a manner similar to miR-122 (miR-122-like), and those that target a single site that bridges sites I and II and masking both G28 and C29 in the 5'UTR (non-miR-122-like). Although the enhancing activity of these non-hepatic miRNAs were lower than those of miR-122, substantial expression was detected in various normal tissues. Furthermore, structural modeling indicated that both miR-122-like and non-miR-122-like miRNAs not only can facilitate the formation of an HCV IRES SLII but also can stabilize IRES 3D structure in order to facilitate binding of SLIII to the ribosome. Together, these results suggest that HCV facilitates miR-122-independent replication in non-hepatic cells through recruitment of miRNAs other than miR-122. And our findings can provide a more detailed mechanism of miR-122-dependent enhancement of HCV-RNA translation by focusing on IRES tertiary structure.

Indexed as

Gene Expression Regulation, ViralProtein BiosynthesisRNA, Viral5' Untranslated RegionsCell Line, TumorHepacivirusHumansMicroRNAsViral ProteinsVirus Replication5' Untranslated RegionsMicroRNAsMIRN122 microRNA, humanRNA, ViralViral Proteins

Identifiers

PMID32574204
PMCPMC7337399
OpenAlexW3037403985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.